MD Anderson orders Ventripoint VMS+ heart analysis systems
Ventripoint Diagnostics (TSXV:VPT) has received an order from MD Anderson Cancer Center in Houstonfor its VMS+ complete heart analysis system for use in clinical evaluations of cancer patients.
"We are very pleased to have the number-one ranked cancer center in the U.S. as the first customer," Desmond Hirson, president of Ventripoint, said in a statement." With our recent market clearance from the FDA, the doctors at MD Anderson will be using the VMS+ to monitor cardiac function in cancer patients."
Chemotherapy agents are known to be cardiotoxic and lead to a significant number of patients acquiring heart dysfunction. Research studies have shown that changes in chamber volumes and function for the right side of the heart are early indicators of the development of heart problems on the left side of the heart in cancer patients and others.
VMS+ provides rapid and accurate assessments for both sides of the heart using conventional 2D ultrasound. These critical measurements are needed to identify patients who require extra cardiac care before, during and after cancer therapy.